CClinicalTrials.gg
Not yet recruitingNCT07316140AprospectiveUpdated Jan 5, 2026

fullPIERS Model in the Prediction of Adverse Maternal Outcomes in Preeclampsia

An observational study in Preeclampsia and Fullpairs, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to female participants. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Sohag University · Observational

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Sex
Female
01

Study summary

Apredictive formula, fullPIERS (Pre-eclampsia Integrated Estimate of Risk Score), can be used to estimate the risk of suffering an adverse outcome using information obtained within 48 hours of admission with pre-eclampsia. The following information is used, serum creatinine, gestational age, platelet count,

Read the detailed description

Inclusion criteria Patients diagnosed with preeclampsia, defined by hypertension (systolic BP

≥140 mmHg and/or diastolic BP ≥90 mmHg, measured twice more than 4 hours apart after 20 weeks gestation) Proteinuria of at least 0.3 g/dl or ≥300 mg of protein in a 24-hour urine collection Urine albumin-creatinine ratio (ACR) ≥30 mg/mmol, or hypertension with end organ dysfunction after20 weeks gestation

02

Conditions studied

  • Preeclampsia
  • Fullpairs

Browse trials for

Keywords

  • Fullpairs score
  • Fullpairs
  • Preeclampsia
03

In context

Pre-Eclampsia

882 studies on the registry are indexed under Pre-Eclampsia; 237 are open to participants now.

This study's planned enrollment of 50 is below the median of 163 across 380 observational studies indexed under Pre-Eclampsia.

Browse Pre-Eclampsia studies →

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

exclude patients who do not meet clinical or laboratory definitions of preeclampsia or related conditions.

Eligibility criteria

  • Inclusion Criteria Female patients diagnosed with preeclampsia. Gestational age ≥ 20 weeks.

Hypertension defined as:

Systolic blood pressure ≥ 140 mmHg and/or Diastolic blood pressure ≥ 90 mmHg, measured on at least two occasions more than 4 hours apart.

Proteinuria defined as:

  • 300 mg protein in a 24-hour urine collection or
  • 0.3 g/dL on urine analysis. Singleton pregnancy. Exclusion Criteria Patients who do not meet the clinical or laboratory diagnostic criteria of preeclampsia.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Validation of the fullPIERS prediction model for adverse maternal outcomes using logistic regression-derived predicted probabilities

    Time frame: 1year

  2. Evaluate the validity of the fullPIERS model in the prediction of adverse maternal outcomes in women with pre-eclampsia in Sohag Governorate, Egypt.

    The collected data are then will be used to calculate the predicted probability of adverse outcomes using the fullPIERS logistic regression equation logit(p)=2.68+(-5.41×10-2×gestational age) +1.23×(chest pain or dyspnea)+(-2.71×10 -2×creatinine) .

    Time frame: 1year

07

Study locations

1 site
  • Obsetatric and gynacological department at Sohag universtiy hospital
    Sohag, Egypt
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Sap

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07316140
Lead sponsor
Sohag University
Responsible party
Alaa Abdellah Mohmed (Residant, Sohag University) — Principal investigator
First posted
Jan 5, 2026
Start date
Jan 1, 2026 (estimated)
Primary completion
Jan 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Jan 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion